文献速递慢性肾脏病遗传性与小管间质肾病

激活素在慢性肾脏病-矿物质骨异常中的作用

The role of activin: the other side of chronic kidney disease-mineral bone disorder?
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

本文综述了激活素A(ActA)在慢性肾脏病-矿物质骨异常(CKD-MBD)中的潜在作用。临床前研究表明,CKD时肾脏、骨骼、血管和心脏中ActA信号增强,提示肾脏产生的内分泌因子不仅促进肾损伤进展,还参与CKD-MBD。文章分析了ActA对肾脏纤维化和炎症的贡献及其在CKD-MBD发展中的作用。

要点

  • CKD-MBD参与CKD心血管高发病率和高死亡率,经典Wnt信号通路在CKD早期即激活。
  • 血管钙化常与骨密度降低和骨转换异常相关,骨与动脉矿化共享通路。
  • 临床前研究显示CKD时ActA信号在肾脏、骨骼、血管和心脏中增强,可能作为内分泌因子参与CKD-MBD。

核心结论

  • ActA信号在CKD时于肾脏、骨骼、血管和心脏中增强,可能作为肾脏产生的内分泌因子参与CKD-MBD。

研究设计与样本

  • 综述,分析ActA对肾脏纤维化和炎症的贡献及其在CKD-MBD发展中的作用。

主要发现

  • CKD-MBD相关通路如经典Wnt信号在CKD最早阶段即激活,参与无动力骨病发展。
  • 这些变化发生于经典矿物质代谢改变(继发性甲旁亢、骨化三醇缺乏、高磷血症)之前。
  • 血管钙化常与骨密度降低和骨转换异常相关,骨与动脉矿化共享通路。
  • 临床前研究显示CKD时肾脏、骨骼、血管和心脏中ActA信号增强。

局限性

  • 当前针对矿物质骨病的临床试验结果被认为不令人满意,需明确骨与血管交叉对话的通路及CKD-MBD新介质。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic kidney disease-mineral bone disorder (CKD-MBD) plays a pivotal role in the excess of cardiovascular morbidity and mortality associated with CKD. There is now a growing awareness that pathways involved in CKD-MBD, like canonical Wnt signalling, are activated from the earliest stages of CKD, playing a role in the development of adynamic bone disease with unknown consequences on vasculature. These changes occur before the classic changes in mineral metabolism: secondary hyperparathyroidism, calcitriol deficiency and hyperphosphataemia. Furthermore, vascular calcification is frequently associated and evolves with decreased bone mineral density and deranged bone turnover, while bone and arterial mineralization share common pathways. Therefore, results of clinical trials focused on mineral bone disorder, aimed at preserving bone and cardiovascular health, are considered unsatisfactory. In order to identify more effective therapeutic strategies, it is necessary to clarify the pathways modulating the cross-talk between bone and vasculature and identify new mediators involved in the pathogenesis of CKD-MBD. Much attention has been paid recently to the role of the transforming growth factor-beta superfamily members in renal disease, and in particular of activin A (ActA). Preclinical studies demonstrate an upgrade of ActA signalling in kidney, skeleton, vasculature and heart during CKD. This supports the idea that an endocrine factor produced in the kidney during renal disease, in addition to promoting the progression of kidney damage, deranges other organs' homoeostasis and participates in CKD-MBD. In this review, we analyse the contribution of ActA to kidney fibrosis and inflammation as well as its role in the development of CKD-MBD.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Cianciolo G, La Manna G, Capelli I, et al. The role of activin: the other side of chronic kidney disease-mineral bone disorder? Nephrol Dial Transplant. 2021. PMID: 32940690. doi:10.1093/ndt/gfaa203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。